

29. **Malmstrom TK, Morley JE.** SARC-F: A Simple Questionnaire to Rapidly Diagnose Sarcopenia. *J Am Med Dir Assoc.* 2013; 14(8): 531–2.
30. **Ohtaka A, Aoki H, Nagata M, et al.** Sarcopenia is a poor prognostic factor of castration-resistant prostate cancer treated with docetaxel therapy. *Prostate Int.* 2019; 7(1): 9–14.
31. **Parkin DM, Bray F, Ferlay J, Pisani P.** Global Cancer Statistics, 2002. *CA Cancer J Clin.* 2005; 55(2): 74–108.
32. **Ibrahim A, Scher N, Williams G, et al.** Approval Summary for Zoledronic Acid for Treatment of Multiple Myeloma and Cancer Bone Metastases. *Clin Cancer Res.* 2003; 9(7): 2394–9.
33. **Katolická J.** Bisfosfonáty u urologických malignit. *Onkologie.* 2013; 7(1): 18–21.
34. **Sharma A, Sinha RJ, Singh V, et al.** Implications of the Fracture Risk Assessment Algorithm for the assessment and improvement of bone health in patients with prostate cancer: a comprehensive review. *Türk Ürol Dergisi/Turkish J Urol.* 2019; 45(4): 245–53.
35. **Shahinian VB, Goodwin JS.** Risk of Fracture after Androgen Deprivation for Prostate Cancer. *N Engl J Med.* 2005; 352(2): 154–64.
36. **Oefelein MG, Ricchiuti V, Conrad W, Resnick MI.** Skeletal fractures negatively correlate with overall survival in men with prostate cancer. *The Journal of Urology.* 2002; 168(3): 1005–1007.
37. **Sweeney CJ, Chen YH, Carducci M, et al.** Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. *N Engl J Med.* 2015; 373(8): 737–46.
38. **Kyriakopoulos CE, Chen YH, Carducci MA, et al.** Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. *J Clin Oncol.* 2018; 36(11): 1080–7.
39. **Gravis G, Boher JM, Chen YH, et al.** Burden of Metastatic Castrate Naïve Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. *Eur Urol.* 2018; 73(6): 847–55.
40. **Fizazi K, Tran N, Fein L, et al.** Abiraterone plus Prednisone in Metastatic, Castration Sensitive Prostate Cancer. *N Engl J Med.* 2017; 377(4): 352–60.
41. **Francini E, Gray KP, Xie W, et al.** Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). *The Prostate.* 2018; 78(12): 889–95.